Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (EQ) is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing innovative therapies for autoimmune and inflammatory disorders with significant unmet medical needs. Founded in 2017, Equillium has quickly established itself as a frontrunner in the biopharmaceutical industry through its focus on novel treatments that modulate the immune system.
The company’s primary product candidate is itolizumab, a unique monoclonal antibody targeting the immune checkpoint receptor CD6. Itolizumab is currently in advanced clinical trials, specifically a Phase 1b/2 trial for the treatment of acute graft-versus-host disease (aGVHD) and a Phase 1 trial for asthma and lupus nephritis. This promising treatment has shown potential in modulating immune responses and reducing inflammation, providing hope for patients suffering from severe autoimmune conditions.
In addition to itolizumab, Equillium's pipeline includes other groundbreaking therapies. EQ101 is a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15. EQ101 is Phase 2-ready and is expected to begin patient enrollment for an alopecia areata study in the second half of 2022. Another noteworthy drug is EQ102, a cytokine inhibitor that targets IL-15 and IL-21, which is also ready for clinical development and will soon begin enrolling patients in a Phase 1 trial, including those with celiac disease.
Equillium’s commitment to addressing immuno-inflammatory disorders is further demonstrated through its strategic partnerships and collaborations. These alliances have enabled the company to enhance its research capabilities, expedite clinical trials, and bring novel treatments to market more efficiently.
Financially, Equillium is well-positioned to continue its research and development activities. The company has secured funding through various channels, ensuring the advancement of its clinical programs. By focusing on diseases with high unmet needs and leveraging its unique approach to immune modulation, Equillium aims to deliver impactful therapies that improve patient outcomes and quality of life.
For the latest updates on Equillium, Inc., including recent achievements and ongoing projects, keep an eye on their official communications and news releases.
Equillium, Inc. (Nasdaq: EQ) announced interim data from the EQUATE clinical trial, showcasing the efficacy of itolizumab as a first-line treatment for acute graft-versus-host disease (aGVHD). Presented by Dr. John Koreth, the findings revealed a remarkable 100% overall response rate in higher dose cohorts, alongside a significant reduction in corticosteroid use by 40-80%. The trial demonstrated itolizumab's safety profile and its mechanism of action, with sustained clinical responses through Day 57. The company anticipates topline results later this year.
Equillium, Inc. (Nasdaq: EQ) appointed Dr. Y. Katherine Xu to its board of directors, effective February 4, 2021. A partner at Decheng Capital, Dr. Xu brings extensive experience in biotechnology and finance. Her expertise is expected to enhance Equillium’s strategic direction as the company advances into later-stage development of itolizumab, aimed at treating severe autoimmune disorders. Dr. Xu noted the significance of targeting the CD6-ALCAM pathway, particularly after promising interim results for treating acute graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) has successfully closed a registered direct offering, raising approximately $30 million in gross proceeds. The offering included 4,285,710 units, with each unit comprising one share of common stock and a warrant for an additional 0.3 shares, priced at $7.00 per unit. The exercise price of the warrants is set at $14.00 per share. Proceeds from this offering will primarily fund the development of the itolizumab pipeline, potential acquisitions, and general corporate purposes.
Equillium, Inc. (Nasdaq: EQ) announced a securities purchase agreement to sell 4,285,710 units at $7.00 each, raising approximately $30 million. Each unit consists of one share of common stock and a warrant for 0.3 additional shares at an exercise price of $14.00. The funds will be used for developing the itolizumab pipeline, acquiring new products, and general corporate needs. The offering closes on February 5, 2021. This offering is registered under a shelf registration statement with the SEC.
Equillium, Inc. (Nasdaq: EQ) announced that interim data from its Phase 1b/2 EQUATE study of itolizumab for acute graft-versus-host disease (aGVHD) will be presented as a late-breaking oral session at the 2021 TCT Meetings, scheduled for February 12, 2021. The study, led by John Koreth, aims to demonstrate the safety and efficacy of itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM pathway, important in T cell activity related to autoimmune disorders. Equillium is focused on treating severe autoimmune and inflammatory conditions with high unmet medical needs.
Equillium, a clinical-stage biotechnology company, announced that its CEO Bruce Steel will present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021, at 6:00 am EST. This presentation will focus on itolizumab, a treatment for severe autoimmune and inflammatory disorders. A webcast of the presentation will be accessible on the company’s website under the “Investors” section for 30 days following the event.
Equillium is dedicated to addressing high unmet medical needs in severe immuno-inflammatory diseases.
Equillium Strengthens Leadership with New Executive Appointments
Equillium, Inc. has announced key executive appointments, including Dolca Thomas, M.D., as executive vice president of research and development and chief medical officer. Dr. Thomas has extensive experience from Principia Biopharma and Roche. The company also appointed Michael Son, Ph.D., Nelson Lugo, and Michael Moore to key roles. These strategic hires aim to advance the development of itolizumab for severe autoimmune diseases, particularly acute graft versus host disease, with several critical readouts expected in the coming year.
Equillium, Inc. presented significant findings regarding itolizumab at the 2020 American Society of Hematology Annual Meeting. The study highlighted the drug's ability to suppress the activity of CD4 and CD8 T cells in patients with acute graft-versus-host disease (aGVHD). With no approved first-line therapies for aGVHD, itolizumab's mechanism of targeting the CD6-ALCAM pathway shows promise. Early data from the EQUATE Phase 1b study also supports its potential role in combination with steroids for treating aGVHD.
Equillium, Inc. (Nasdaq: EQ) has announced a virtual Investor and Analyst Day on December 4, 2020, from 9:30 a.m. to 12:00 p.m. ET, focusing on its leading drug candidate, itolizumab, a monoclonal antibody for treating severe autoimmune disorders, including aGVHD, lupus, and uncontrolled asthma. Key presentations will feature Dr. John Koreth from Dana-Farber Cancer Institute and the company's executives. Following presentations, there will be a Q&A session. A webcast will be available for 30 days on the company's Investor Relations website.
Equillium has announced it will not proceed with the EQUINOX Phase 3 clinical trial for itolizumab in COVID-19 patients, citing advancements in vaccines and treatments. CEO Bruce Steel emphasized the decision was strategic amidst a changing treatment landscape. Instead, the company will focus on expanding the itolizumab program for acute graft-versus-host disease, lupus, and asthma studies. The next pipeline updates are expected on December 4, coinciding with the Analyst Day.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
What does Equillium, Inc. specialize in?
What is itolizumab?
What other products are in Equillium's pipeline?
Where is Equillium, Inc. headquartered?
When was Equillium, Inc. founded?
What are the current clinical trials for itolizumab?
What is the focus of EQ101?
What conditions is EQ102 targeting?
How is Equillium funded?
How can I stay updated on Equillium, Inc.'s latest news?
